NYSE:AGN

Allergan Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$193.02
0.00 (0.00 %)
(As of 05/8/2020)
Add
Compare
Today's Range
$191.64
$193.38
50-Day Range
$184.04
$193.89
52-Week Range
$114.27
$202.21
Volume12.44 million shs
Average Volume4.01 million shs
Market Capitalization$63.50 billion
P/E RatioN/A
Dividend Yield1.53%
Beta1.2

Receive AGN News and Ratings via Email

Sign-up to receive the latest news and ratings for Allergan and its competitors with MarketBeat's FREE daily newsletter.


Allergan logo

About Allergan

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. In addition, it develops medical and cosmetic treatments; therapies for non-alcoholic steatohepatitis and other liver diseases; inhibitor for the treatment of psoriasis and other autoimmune disorders; atopic dermatitis drug candidate; peri-ocular rings for extended drug delivery and reducing elevated intraocular pressure in glaucoma patients; and treatments for neurodegenerative disorders, including Alzheimer's disease. Further, the company develops RST-001, a novel gene therapy for the treatment of retinitis pigmentosa; small molecule therapeutics for inflammatory and fibrotic diseases; topical medicines for fat reduction; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; and strategic alliance and option agreement with Editas Medicine, Inc. Allergan plc also has licensing agreements with Assembly Biosciences, Inc.; MedImmune; and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

Headlines

FDA Approves Allergans Dalivance - Benzinga
FDA Approves Allergan's Dalivance - Benzinga
July 23, 2021 |  benzinga.com
See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.88 out of 5 stars

Medical Sector

488th out of 2,218 stocks

Pharmaceutical Preparations Industry

242nd out of 869 stocks

Analyst Opinion: 0.0Community Rank: 4.0Dividend Strength: 2.5Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Allergan (NYSE:AGN) Frequently Asked Questions

What stocks does MarketBeat like better than Allergan?

Wall Street analysts have given Allergan a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Allergan wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Allergan's earnings last quarter?

Allergan plc (NYSE:AGN) announced its earnings results on Monday, February, 10th. The company reported $5.22 EPS for the quarter, beating the consensus estimate of $4.57 by $0.65. The business had revenue of $4.35 billion for the quarter, compared to the consensus estimate of $4.09 billion. Allergan had a positive trailing twelve-month return on equity of 8.46% and a negative net margin of 15.44%. The company's revenue was up 6.6% on a year-over-year basis. During the same period last year, the business posted $4.29 EPS.
View Allergan's earnings history
.

Is Allergan a good dividend stock?

Allergan pays an annual dividend of $2.96 per share and currently has a dividend yield of 1.53%. The dividend payout ratio of Allergan is 16.78%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Allergan will have a dividend payout ratio of 16.33% next year. This indicates that Allergan will be able to sustain or increase its dividend.
View Allergan's dividend history.

Who are Allergan's key executives?

Allergan's management team includes the following people:
  • Mr. Brenton L. Saunders, Chairman, Pres & CEO (Age 49)
  • Mr. William Meury, Exec. VP & Chief Commercial Officer (Age 51)
  • Dr. C. David Nicholson, Exec. VP and Chief R&D Officer (Age 64)
  • Mr. Matthew M. Walsh, Exec. VP & CFO (Age 52)
  • Mr. Wayne R. Swanton, Exec. VP of Global Operations (Age 51)

Who are some of Allergan's key competitors?

What other stocks do shareholders of Allergan own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergan investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), NIC (EGOV), United Rentals (URI) and Transocean (RIG).

What is Allergan's stock symbol?

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

What is Allergan's stock price today?

One share of AGN stock can currently be purchased for approximately $193.02.

How much money does Allergan make?

Allergan has a market capitalization of $63.50 billion and generates $16.09 billion in revenue each year. The company earns $-5,271,000,000.00 in net income (profit) each year or $17.64 on an earnings per share basis.

How many employees does Allergan have?

Allergan employs 17,400 workers across the globe.

What is Allergan's official website?

The official website for Allergan is www.allergan.com.

Where are Allergan's headquarters?

Allergan is headquartered at CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400.

How can I contact Allergan?

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]


This page was last updated on 7/27/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.